MedTrace Logo

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

NCT05819684 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2024-06-21

No results posted yet for this study

Summary

This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SHR-4602 for injection

be administered via intravenous (IV) infusion

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-18
Primary Completion
2025-05-30
Completion
2026-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05819684 on ClinicalTrials.gov